SGLT-2阻害薬の新規使用者における心血管系アウトカムの比較有効性

基本情報

NCT ID

NCT02993614

ステータス

完了

試験のフェーズ

-

試験タイプ

観察

目標被験者数

99,999

治験依頼者名

AstraZeneca

概要

CVD-REAL is a multinational, observational cohort study in patients with type 2 diabetes mellitus evaluating the comparative effectiveness of initiating treatment with a sodium-glucose co-transporter-2 (SGLT-2) inhibitor versus another glucose-lowering drug. This study will compare the risk of all-cause mortality and clinically relevant cardiovascular (CV) outcomes respectively in patients who are new users of SGLT-2 inhibitors with those who are new users of other glucose-lowering drugs. CVD-REAL is aiming to collect data from approximately 4 million patients overall, from twelve countries across three major world regions.

対象疾患

依頼者（Sponsor）